Opioid Prescription Rates Higher in Cancer Survivors

This article originally appeared here.
Share this content:
Opioid Prescription Rates Higher in Cancer Survivors
Opioid Prescription Rates Higher in Cancer Survivors

THURSDAY, Aug. 10, 2017 (HealthDay News) -- Substantially higher opioid prescribing rates persist among cancer survivors, even long after attaining survivorship, according to a study published online Aug. 7 in Cancer.

In an effort to examine differences in opioid prescribing rates, Rinku Sutradhar, Ph.D., from University of Toronto, and colleagues matched individuals (aged 18 to 64 years of age and at least five years past their cancer diagnosis) to controls without a prior cancer diagnosis based on sex and calendar year of birth. Follow-up ended with any indication of cancer recurrence or new cancer diagnosis.

The researchers found that the rate of opioid prescribing was 1.22 times higher among survivors than among matched controls. Significantly higher prescribing rates were seen in individuals from lower income quintiles, who were younger, who were from rural neighborhoods, and who had a greater number of comorbidities. Prescribing rates were not associated with sex.

"This raises concerns about the diagnosis and management of chronic pain problems among survivors stemming from their cancer diagnosis or treatment," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths